SW 1353 Cell Line

Brief Introduction
Product List

General Information
Organism	Homo sapiens, human
Cell Line Description	SW 1353 is a human chondrosarcoma cell line established in 1977 by Albert Leibovitz and colleagues at the Scott and White Clinic in Temple, Texas. The cell line was derived from a primary surgically resected bone tumor specimen from the humerus of a 72-year-old Caucasian female diagnosed with Grade II chondrosarcoma. SW 1353 cells grow as an adherent monolayer and exhibit fibroblast-like or fibroblast/polygonal morphological characteristics. In the fields of musculoskeletal biology, orthopedics, and cartilage research, SW 1353 is recognized as the preferred "gold standard" human in vitro model for studying chondrocyte inflammatory responses and osteoarthritis (OA). Upon stimulation with pro-inflammatory cytokines such as IL-1β, TNF-α, or IL-6, SW 1353 cells reliably mimic primary articular chondrocytes by producing matrix metalloproteinases (MMPs), ADAMTS enzymes, and inflammatory mediators.
Tissue	Bone / Cartilage; derived from primary lesion in the Humerus
Cell Type	Chondrocyte / Chondrosarcoma Epithelioid-Fibroblastic Cell
Population / Ancestry	Caucasian
Disease	Grade II Chondrosarcoma
Morphology	Fibroblast-like / Polygonal monolayer
Gender	Female
Age	72 years
Product Format	Frozen
Growth Mode	Adherent
Biosafety Level	1 (Biosafety classification matches standard international guidelines for non-infectious human tumor cells)
Applications	1. A "gold-standard" human in vitro alternative model for osteoarthritis (OA) research, designed to evaluate cytokine-induced (IL-1β/TNF-α) cartilage catabolic pathways; 2. Screening for anti-inflammatory and chondroprotective drugs, as well as disease-modifying osteoarthritis drugs (DMOADs); 3. Elucidating the transcriptional regulatory mechanisms of matrix metalloproteinases (MMP-1, MMP-3, MMP-13) and aggrecanases (ADAMTS-4, ADAMTS-5); 4. Investigating the biological characteristics, chemotherapy resistance, and targeted kinase inhibition strategies regarding chondrosarcoma; 5. Establishing 3D alginate/pellet cartilage culture systems to study extracellular matrix synthesis and chondrogenic markers.
Shipped In	Dry ice
Storage Temperature	−196°C
Characteristics
Tumorigenic	Yes; forms progressively expanding chondrosarcomas when inoculated subcutaneously into athymic nude rodents.
Transformant	None; immortalized spontaneously from advanced clinical primary tumor tissue.
Oncogenic Drivers & Key Mutations	1. IDH2 status: Harboring the classic chondrosarcoma-associated somatic mutation p.Arg172Ser (c.514A>C) in the IDH2 gene; this mutation confers neomorphic enzymatic activity resulting in the production of 2-hydroxyglutarate (2-HG). 2. TP53 status: Mutated; harboring the missense mutation p.Arg273His (c.818G>A) in the TP53 gene. 3. KRAS status: Mutated; harboring the activating mutation p.Gly12Cys. 4. CDKN2A status: Homozygous deletion. 5. Microsatellite status: Stable (MSS).
Karyotype	Human hyperdiploid/hypotriploid karyotype with modal chromosome count around 59-63.
Growth Kinetics	Robust adherent expansion; typical population doubling time spans approximately 24 to 32 hours.
Mycoplasma Test	Negative
Culture Conditions and Handling
Subculturing	1. Completely aspirate and discard the complete culture medium from the culture vessel. 2. Gently rinse the cell monolayer with sterile, Ca2+/Mg2+-free PBS to remove residual serum containing trypsin inhibitors. 3. Add 1.0 to 2.5 mL of 0.25% trypsin-0.53 mM (0.02%) EDTA solution, pre-warmed to the appropriate temperature, ensuring the cell layer is completely covered. 4. Incubate at 37°C for 2 to 5 minutes; monitor under an inverted microscope until the cells become rounded, loosen, and completely detach. 5. Add an equal volume of pre-warmed complete growth medium to immediately neutralize trypsin activity. 6. Gently resuspend the cells by pipetting and centrifuge at approximately 125 × g for 5 minutes; carefully discard the supernatant, gently resuspend the cells in fresh complete growth medium, and then distribute them into new culture vessels.
Medium Renewal	2 to 3 times per week
Subcultivation Ratio	Split confluent cultures (80% density) at a standard ratio of 1:3 to 1:8. Maintain active growth by subculturing before reaching complete 100% confluence.
Culture Conditions	Atmosphere: Air, 100% (if using L-15 medium) OR Air, 95%; CO2, 5% (if using DMEM / DMEM-F12 base); Temperature: 37°C
Cryopreservation	90% Complete culture growth medium + 10% DMSO (or 50% Basal medium + 40% FBS + 10% DMSO)

Cat.No.	Product Name	Price
CSC-RO01224	Cas9 Stable Cell Line - SW 1353	Inquiry
CSC-RR00716	Luciferase Reporter Cell Line - SW 1353	Inquiry
CSC-RO01656	OVAL Stable Cell Line - SW 1353	Inquiry
CSC-RO01909	GFP/OVAL Stable Cell Line - SW 1353	Inquiry
CSC-RO02162	Luc/OVAL Stable Cell Line - SW 1353	Inquiry
CSC-RO02415	GFP/Luc/OVAL Stable Cell Line - SW 1353	Inquiry

The above is only part of a part of cell line products. If you don't find the cell line you want, Creative Biogene can also provide stable cell line generation service with the best prices and fastest turnaround time for you! Contact us for more information or to request a quote.

* For research use only. Not intended for any clinical use.

Quick Inquiry